Dimerix Bioscience and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Sign Agreement to Use GPCR-HIT Platform in Discovery Program  
4/20/2010 9:09:57 AM

PERTH, Australia--(BUSINESS WIRE)--Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of ’best in class’ lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company.